Hypotensive and orthostatic activities of a variety of orally administered antihypertensive drugs were concurrently evaluated in conscious spontaneously hypertensive rats and attempts were made to relate these responses to effects on peripheral sympathetic function. The alpha-adrenergic blockers phentolamine and prazosin and the adrenergic neuron blocker guanethidine inhibited compensatory responses to upright tilt at antihypertensive doses. The ganglionic blocker mecamylamine produced milder inhibition. The centrally active agents methyldopa and clonidine and the vasodilator minoxidil did not alter tilt responses appreciably. In contrast, the vasodilator hydralazine exerted marked postural effects. Autonomic interactions were evaluated in pithed rats. alpha-Adrenergic receptor, adrenergic neuron and ganglionic blockers inhibited pressor responses to i.v. phenylephrine and/or to sympathetic nerve activation. Vasodilators did not produce specific effects. The tilt and pithed rat models, when used in conjunction, are very useful in predicting orthostatic potential of drugs in humans although absolute correlation cannot be expected.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/10641968109033662 | DOI Listing |
Europace
January 2025
Department of Clinical Sciences, Lund University, Malmö, Sweden.
Background: Orthostatic hypotension (OH) is an important differential diagnosis in unexplained syncope. Neurogenic OH (nOH) has been postulated to differ from non-neurogenic OH (non-nOH), yet pathophysiological differences are largely unexplored. We aimed to investigate etiology and tilt table test (TTT)-induced hemodynamic responses in symptomatic OH patients.
View Article and Find Full Text PDFJ Formos Med Assoc
January 2025
Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Controlling hypertension has become an important issue in the elderly population in whom neurological comorbidities are highly prevalent. Most of the large-scale trials focusing on hypertension management in older populations have excluded patients with comorbid neurological disorders. However, this population requires special considerations, as the benefits of antihypertensive agents are mostly uncertain and there is a higher risk of adverse events.
View Article and Find Full Text PDFMov Disord Clin Pract
January 2025
TSE/Prion Biochemistry Section, DIR, National Institute of Allergy and Infectious Diseases (NIAID), Hamilton, Montana, USA.
Background: Cerebrospinal fluid (CSF) α-synuclein seeding activity (SSA) via a seed amplification assay might predict central Lewy body diseases (LBD) in at-risk individuals.
Objective: The aim was to assess CSF SSA in a prospective, longitudinal study.
Methods: Participants self-reported risk factors were genetics, olfactory dysfunction, dream enactment behavior, orthostatic intolerance, or hypotension; individuals who had ≥3 confirmed risk factors underwent CSF sampling and were followed for up to 7.
Eur J Prev Cardiol
January 2025
CH Saint Joseph et Saint Luc. Lyon, France.
Due to the aging population, focusing on healthy aging has become a global priority. Cardiovascular diseases (CVDs) and frailty, characterized by increased vulnerability to adverse stress and health events, interact synergistically in advanced age. In older adults, hip fractures are a frequent dramatic "life-transition" event.
View Article and Find Full Text PDFClin Neuropharmacol
January 2025
MedStar Georgetown University Hospital, Washington, DC.
Introduction: Adjunctive therapies to treat OFF episodes resulting from long-term levodopa treatment in Parkinson disease (PD) are hampered by safety and tolerability issues. Istradefylline offers an alternative mechanism (adenosine A2A receptor antagonist) and therefore potentially improved tolerability.
Methods: A systematic review of PD adjuncts published in 2011 was updated to include randomized controlled trials published from January 1, 2010-April 15, 2019.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!